Brokers Offer Predictions for Repligen Co.’s Q1 2024 Earnings (NASDAQ:RGEN)
Repligen Co. (NASDAQ:RGEN – Free Report) – Equities researchers at Zacks Research cut their Q1 2024 earnings per share estimates for shares of Repligen in a research note issued to investors on Wednesday, March 13th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $0.29 per share for the quarter, down from their previous estimate of $0.35. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. Zacks Research also issued estimates for Repligen’s Q2 2024 earnings at $0.33 EPS, Q4 2024 earnings at $0.44 EPS, FY2024 earnings at $1.45 EPS, Q1 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.56 EPS and FY2026 earnings at $2.92 EPS.
Repligen (NASDAQ:RGEN – Get Free Report) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. During the same period in the prior year, the firm posted $0.68 EPS. Repligen’s quarterly revenue was down 16.6% on a year-over-year basis.
RGEN has been the subject of several other research reports. JPMorgan Chase & Co. raised their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus lifted their price target on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Benchmark lowered Repligen from a “buy” rating to a “hold” rating in a report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $196.70.
Read Our Latest Research Report on RGEN
Repligen Price Performance
Repligen stock opened at $193.58 on Friday. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $10.80 billion, a PE ratio of 268.86, a P/E/G ratio of 6.36 and a beta of 1.03. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13. The stock has a 50-day moving average price of $191.23 and a two-hundred day moving average price of $170.45.
Insider Activity at Repligen
In other news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,597 shares of company stock worth $5,039,532. Insiders own 1.10% of the company’s stock.
Institutional Investors Weigh In On Repligen
A number of large investors have recently added to or reduced their stakes in RGEN. PNC Financial Services Group Inc. lifted its position in shares of Repligen by 6.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,723 shares of the biotechnology company’s stock worth $1,077,000 after buying an additional 333 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in Repligen by 8.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 28,126 shares of the biotechnology company’s stock valued at $5,427,000 after purchasing an additional 2,143 shares during the last quarter. Raymond James Trust N.A. lifted its position in Repligen by 37.4% in the 1st quarter. Raymond James Trust N.A. now owns 2,331 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 634 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Repligen by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 229,785 shares of the biotechnology company’s stock valued at $43,221,000 after purchasing an additional 11,121 shares during the last quarter. Finally, Sei Investments Co. lifted its position in Repligen by 18.5% in the 1st quarter. Sei Investments Co. now owns 59,917 shares of the biotechnology company’s stock valued at $11,331,000 after purchasing an additional 9,352 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Receive News & Ratings for Repligen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Repligen and related companies with MarketBeat.com’s FREE daily email newsletter.
